Spectrum of mutations in RARS-T patients includes TET2 and ASXL1 mutations

Leukemia Research

Volumn 34, Issue 8, 2010, Pages 969-973

  Szpurka, Hadrian ^a   Jankowska, Anna M ^a   Makishima, Hideki ^a   Bodo, Juraj ^a   Bejanyan, Nelli ^a   Hsi, Eric D ^a   Sekeres, Mikkael A ^a   Maciejewski, Jaroslaw P ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

ASXL1; JAK2 V617F; MPL W515L; RARS T; STAT5; TET2

Indexed keywords

STAT5 PROTEIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DISEASE ASSOCIATION; ENZYME ACTIVATION; GENE; GENE MUTATION; HUMAN; IMMUNOHISTOCHEMISTRY; KARYOTYPE; PHENOTYPE; PRIORITY JOURNAL; REFRACTORY ANEMIA WITH RINGED SIDEROBLASTS; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOCYTOSIS;

AGED; AGED, 80 AND OVER; ANEMIA, REFRACTORY; ANEMIA, SIDEROBLASTIC; DNA-BINDING PROTEINS; HUMANS; IMMUNOENZYME TECHNIQUES; MIDDLE AGED; MUTATION; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTO-ONCOGENE PROTEINS; REPRESSOR PROTEINS; THROMBOCYTOSIS;

EID: 77953616961     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2010.02.033     Document Type: Article

References (30)

1. Szpurka H., Tiu R., Murugesan G., Aboudola S., Hsi E.D., et al. Refractory anemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T), another myeloproliferative condition characterized by JAK2 V617F mutation. Blood 2006, 108(October (7)):2173-2181.
2. Wang S.A., Hasserjian R.P., Loew J.M., Sechman E.V., Jones D., et al. Refractory anemia with ringed sideroblasts associated with marked thrombocytosis harbors JAK2 mutation and shows overlapping myeloproliferative and myelodysplastic features. Leukemia 2006, 20(September (9)):1641-1644.
3. Boissinot M., Garand R., Hamidou M., Hermouet S. The JAK2-V617F mutation and essential thrombocythemia features in a subset of patients with refractory anemia with ring sideroblasts (RARS). Blood 2006, 108(September (5)):1781-1782.
4. Ceesay M.M., Lea N.C., Ingram W., Westwood N.B., Gaken J., et al. The JAK2 V617F mutation is rare in RARS but common in RARS-T. Leukemia 2006, 20(November (11)):2060-2061.
5. Renneville A., Quesnel B., Charpentier A., Terriou L., Crinquette A., et al. High occurrence of JAK2 V617 mutation in refractory anemia with ringed sideroblasts associated with marked thrombocytosis. Leukemia 2006, 20(November (11)):2067-2070.
6. 9/L) and ringed sideroblasts more than 15% considered as MDS/MPD, unclassifiable. Blood 2007, 109(February (3)):1334-1335.
7. Schmitt-Graeff A.H., Teo S.S., Olschewski M., Schaub F., Haxelmans S., et al. JAK2V617F mutation status identifies subtypes of refractory anemia with ringed sideroblasts associated with marked thrombocytosis. Haematologica 2008, 93(January (1)):34-40.
8. Schmitt-Graeff A., Thiele J., Zuk I., Kvasnicka H.M. Essential thrombocythemia with ringed sideroblasts: a heterogeneous spectrum of diseases, but not a distinct entity. Haematologica 2002, 87(April (4)):392-399.
9. Pardanani A.D., Levine R.L., Lasho T., Pikman Y., Mesa R.A., et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood 2006, 108(November (10)):3472-3476.
10. Pikman Y., Lee B.H., Mercher T., McDowell E., Ebert B.L., et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med 2006, 3(July (7)):e270.
11. Szpurka H., Gondek L.P., Mohan S.P., Hsi E.D., Theil K.S., et al. UPD1p indicates the presence of MPL W515L mutation in RARS-T, a mechanism analogous to UPD9p and JAK2 V617F mutation. Leukemia 2009, 23(March (3)):610-614.
12. Mohamedali A.M., Smith A.E., Gaken J., Lea N.C., Mian S.A., et al. Novel TET2 mutations associated with UPD4q24 in myelodysplastic syndrome. J Clin Oncol 2009, 27(August (24)):4002-4006.
13. Langemeijer S.M., Kuiper R.P., Berends M., Knops R., Aslanyan M.G., et al. Acquired mutations in TET2 are common in myelodysplastic syndromes. Nat Genet 2009, 41(July (7)):838-842.
14. Delhommeau F., Dupont S., Della V.V., James C., Trannoy S., et al. Mutation in TET2 in myeloid cancers. N Engl J Med 2009, 360(May (22)):2289-2301.
15. Jankowska A.M., Szpurka H., Tiu R.V., Makishima H., Afable M., et al. Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasms. Blood 2009, 113(June (25)):6403-6410.
16. Tefferi A., Lim K.H., Abdel-Wahab O., Lasho T.L., Patel J., et al. Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML. Leukemia 2009, 23(July (7)):1343-1345.
17. Abdel-Wahab O., Mullally A., Hedvat C., Garcia-Manero G., Patel J., et al. Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood 2009, 114(July (1)):144-147.
18. Flach J., Dicker F., Schnittger S., Kohlmann A., Haferlach T., et al. Mutations of JAK2 and TET2, but not CBL are detectable in a high portion of patients with refractory anemia with ring sideroblasts and thrombocytosis (RARS-T). Haematologica 2009, (November).
19. Tefferi A., Pardanani A., Lim K.H., Abdel-Wahab O., Lasho T.L., et al. TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis. Leukemia 2009, 23(May (5)):905-911.
20. Gelsi-Boyer V., Trouplin V., Adelaide J., Bonansea J., Cervera N., et al. Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia. Br J Haematol 2009, 145(June (6)):788-800.
21. Carbuccia N., Murati A., Trouplin V., Brecqueville M., Adelaide J., et al. Mutations of ASXL1 gene in myeloproliferative neoplasms. Leukemia 2009, 23(November (11)):2183-2186.
22. Gondek L.P., Dunbar A.J., Szpurka H., McDevitt M.A., Maciejewski J.P. SNP array karyotyping allows for the detection of uniparental disomy and cryptic chromosomal abnormalities in MDS/MPD-U and MPD. PLoS ONE 2007, 2(11):e1225.
23. Kralovics R., Guan Y., Prchal J.T. Acquired uniparental disomy of chromosome 9p is a frequent stem cell defect in polycythemia vera. Exp Hematol 2002, 30(March (3)):229-236.
24. Vannucchi A.M., Antonioli E., Guglielmelli P., Pardanani A., Tefferi A. Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal. Leukemia 2008, 22(July (7)):1299-1307.
25. Vannucchi A.M., Antonioli E., Guglielmelli P., Pancrazzi A., Guerini V., et al. Characteristics and clinical correlates of MPL 515W>L/K mutation in essential thrombocythemia. Blood 2008, 112(August (3)):844-847.
26. Ono R., Taki T., Taketani T., Taniwaki M., Kobayashi H., et al. LCX, leukemia-associated protein with a CXXC domain, is fused to MLL in acute myeloid leukemia with trilineage dysplasia having t(10;11)(q22;q23). Cancer Res 2002, 62(July (14)):4075-4080.
27. Lorsbach R.B., Moore J., Mathew S., Raimondi S.C., Mukatira S.T., et al. TET1, a member of a novel protein family, is fused to MLL in acute myeloid leukemia containing the t(10;11)(q22;q23). Leukemia 2003, 17(March (3)):637-641.
28. Tahiliani M., Koh K.P., Shen Y., Pastor W.A., Bandukwala H., et al. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science 2009, 324(May (5929)):930-935.
29. Swerdlow S.H., Campo E., Harris N.L., Jaffe E.S., Pileri S.A., et al. WHO classification of tumours of haematopoietic and lymphoid tissues 2008, IARC, Lyon.
30. 9/l. Ann Hematol 2008, 87(May (5)):413-415.